¹⁹F (Perfluoropropane) MRI
ConditionHealthy Volunteers - Male and Female
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorAlexei Ouriadov
About this trial
Healthy volunteers aged 18 to 85 will undergo ¹⁹F (perfluoropropane) MRI to support the development of imaging sequences, reconstruction algorithms, and hardware necessary for acquiring high-spatial resolution lung images. The study will also evaluate signal-to-noise ratio, contrast-to-noise ratio, spatial resolution, scan duration, and pulmonary gas exchange measurements derived from ¹⁹F (perfluoropropane) MRI.
Eligibility criteria
Qualifiers
Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature.
Provision of written, informed consent prior to any study specific procedures.
Males and females aged 18 to 85 years.
Participant must be able to perform a breath-hold for 16s.
Disqualifiers
Patient has an MR incompatible implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist).
In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.
Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit.
Participant is unable to perform spirometry maneuvers.
Trial design
Treatments tested in this trial
- 19F(perfluoropropane) MRI
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Alexei Ouriadov
Lead sponsor
Western University
Sponsor institution
St. Joseph's Health Care London
Collaborator
Source ClinicalTrials.gov